Author:
Radisch Sabine,Poltorak Mateusz P.,Wagner Michaela,Cletiu Vlad,Radisch Christian,Treise Irina,Pann Steffi,Weigt Alexis,Artner Sophie,Dreher Stefan,Fechner Fabian,Borjan Bojana,Fraessle Simon P.,Effenberger Manuel,Benke Eileen,Navratil Gottfried,Hentschel Norbert,Busch Dirk H.,Schmidt Thomas,Stemberger Christian,Germeroth Lothar
Abstract
AbstractLarge-scale target cell isolation from patient blood preparations is one of the critical operations during drug product manufacturing for personalized cell therapy in immuno-oncology. Use of high-affinity murine antibody coated magnetic nanoparticles that remain on isolated cells is the current standard applied for this purpose. Here, we present the transformation of previously described technology — non-magnetic immunoaffinity column chromatography-based cell selection with reversible reagents into a new clinical-grade cell isolation platform called Automated Traceless Cell affinity chromatography (ATC). ATC is a fully closed and GMP-compliant cell selection and manufacturing system. Reversibility of reagents enables (sequential) positive cell selection, optionally in combination with depletion columns, enabling capture of highly specific cell subsets. Moreover, synergy with other Streptamer-based technologies allows novel uses beyond cell isolation including integrated and automated on-column target cell activation. In conclusion, ATC technology is an innovative as well as versatile platform to select, stimulate and modify cells for clinical manufacturing and downstream therapies.
Publisher
Springer Science and Business Media LLC
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献